25/100BRoivant Sciences company profile
- CEO
- Matthew Gline
- Employees
- 721
- Headquarters
- 50 Broadway, London, GL SW1H 0DB, GB
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO date
- 8 Dec 2020
- Stock exchange
- NASDAQ
- ISIN
- BMG762791017
Website:roivant.com
About the company
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Employees
Roivant Sciences had about 721 employees at the end of fiscal year 2025 (31 March 2026), by its annual report. That is 3.9% fewer than a year before.
Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.
Who owns Roivant Sciences
Institutions such as funds, banks and insurers held 77.8% of Roivant Sciences's shares on 30 June 2026, 519 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Common questions about Roivant Sciences
Source: Financial Modeling Prep